TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22205203
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Bortezomib, Gemcitabine, Liposomal Doxorubicin)
Study: 20631326
Drug: Zinc administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc administration (10 mg/d for children 2-11 months and 20 mg/d for children ≥ 12 months) for 14 days
Study: 20631326
Drug: Zinc administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc administration
Study: 18551467
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Study: 18551467
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Study: 18551467
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (0.3 g extract/250 ml) with 5 mg folic acid
Study: 18551467
Drug: Water (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (reference drink) with 0.4 mg and 5 mg folic acid
Study: 17002050
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen '2b' (isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolone (ofloxacin, ciprofloxacin, levofloxacin), and canamycin (amikacin))
Study: 17002050
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen '2a' (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin)
Study: 17002050
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen '2b'
Study: 17002050
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen '2a'
Study: 1706562
Drug: Clemastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 4 mg + Cimetidine 400 mg i.v. 15 min before implantation
Study: 6765509
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of triamcinolonehexacetonide (TH)
Study: 6765509
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of the combination betamethasone acetate and betamethasone disodiumphosphate (BM)
Study: 28685396
Drug: Bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion HCl immediate release (IR) 75 mg
Study: 28685396
Drug: Bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion HCl sustained release (SR) 100/150 mg
Study: 28685396
Drug: Bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion HCl extended release (ER) 150/300 mg
Study: 24238630
Drug: Web-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based treatment program
Study: 17885577
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment (open-label and double-blind)
Study: 7874154
Drug: ATP‐E (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP‐E (0.2 g.kg‐1.day‐1)
Study: 3282867
Drug: Sustained action
Normalized name: TABLET, BUCCAL SUSTAINED ACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained action tiaprofenic acid 600 mg once daily
Study: 3282867
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release indomethacin 75 mg once daily
Study: 31811952
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (2-3 sessions combined with daily exercise)
Study: 31811952
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber supplementation (3.5 g plantago ovata per day)
Study: 9579209
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of meglumine antimoniate (MA; 15 mg Sb/kg.day) on 6 days/week for 12 injections.
Study: 9579209
Drug: Intralesional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional administration of meglumine antimoniate (MA; 0.2‐0.8 ml/lesion) every other day for 30 days.
Study: 3300518
Drug: Clonidine (0.0075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.0075 mg/kg/day)
Study: 3300518
Drug: Clonidine (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.015 mg/kg/day)
Study: 3300518
Drug: Clonidine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (twice a day)
Study: 3300518
Drug: Clonidine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (in patients receiving neuroleptic agents)
Study: 3300518
Drug: Clonidine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (low dose vs high dose)
Study: 30001903
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (manual therapy + motor control exercises + inspiratory muscle training)
Study: 27296490
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral methotrexate weekly
Study: 27296490
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mycophenolate mofetil twice daily
Study: 24497828
Drug: IL-7 administration
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-7 administration (recombinant human IL-7 at 20 µg/kg, three subcutaneous injections)
Study: 24497828
Drug: IL-7 administration
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-7 administration
Study: 24349532
Drug: IL‐18 ‐137
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐18 ‐137 polymorphism (G/C heterozygotes)
Study: 24349532
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to oral cancer-related environmental risk factors (areca, alcohol, tobacco)
Study: 24349532
Drug: IL‐18 ‐137
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐18 ‐137 G/C alleles
Study: 18237588
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment at cuff pressures of 75 mm Hg
Study: 18237588
Drug: Enhanced external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced external counterpulsation (EECP) and Sham treatment
Study: 12627927
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) for outpatients
Study: 12627927
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin for inpatients
Study: 11802676
Drug: Medication Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Placebo
Study: 7845799
Drug: Rate augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate augmentation factor set to low with medium speed of response
Study: 7845799
Drug: Rate augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate augmentation factor set to medium with fast speed of response
Study: 7845799
Drug: Rate augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate augmentation factor set to high with fast speed of response
Study: 7845799
Drug: Rate augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate augmentation factor
Study: 29631810
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle)
Study: 29631810
Drug: sorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib monotherapy (400 mg orally twice daily)
Study: 29631810
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus hepatic arterial infusion chemotherapy
Study: 29631810
Drug: sorafenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib monotherapy
Study: 26451086
Drug: Generic MT
Normalized name: MT-0169
DrugBank: MT-0169 (DB17430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic MT 5 mg chewable tablets
Study: 26451086
Drug: Branded Singulair(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded Singulair(®) pediatric 5 mg chewable tablets
Study: 24553281
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent CPP-ACP cream
Study: 8941023
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of rt-PA
Study: 1357924
Drug: Protopam chloride
Normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protopam chloride (1,000 mg intravenously)
Study: 1357924
Drug: Protopam chloride
Normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protopam chloride (oral and parenteral administration)
Study: 1357924
Drug: Protopam chloride
Normalized name: Protopam Chloride
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protopam chloride (large doses)
Study: 30857448
Drug: Oral leukoplakia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leukoplakia (OL) patients
Study: 24373019
Drug: Imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1 mg twice daily (group A)
Study: 24373019
Drug: Propiverine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 20 mg once daily (group B)
Study: 22406705
Drug: Lycopene 8
Normalized name: multivit,calcium,minerals/iron fumar/folic ac/vit K/lycopene 8 mg iron-200 mcg-60 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 8 mg/day for 8 weeks
Study: 18077928
Drug: gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemifloxacin 320 mg/tablet (test product)
Study: 18077928
Drug: factive 320
Normalized name: Factive 320mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: factive 320 mg/tablet (reference product)
Study: 10575269
Drug: BCG (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (81 mg, 6 weekly instillations)
Study: 15643181
Drug: Epirubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (50 mg, 8 weekly instillations)
Study: 2105638
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 1,200 mg/d for 16 weeks
Study: 2105638
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observation without changes in prescription)
Study: 6975168
Drug: Cotrimoxazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole)
Study: 6975168
Drug: Co-tri-famole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-tri-famole (80 mg trimethoprim and 400 mg sulfamoxole)
Study: 23919432
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 μg·kg(‐1))
Study: 23181640
Drug: Hyaluronidase (HAase)
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase (HAase) injection (20,000 turbidity-reducing units)
Study: 19261295
Drug: Sapropterin dihydrochloride,
Normalized name: Sapropterin Dihydrochloride, 100 mg oral tablet, soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin dihydrochloride, 20 mg/kg/d for 10 weeks
Study: 8265301
Drug: Sn-mesoporphyrin (SnMP)
Normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn-mesoporphyrin (SnMP) at a dose of 6 mumol/kg body weight
Study: 21357906
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 25 mg/d for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Study: 21357906
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks followed by fluticasone propionate nasal drops, 400 µg twice daily for 8 weeks and fluticasone propionate nasal spray, 200 µg twice daily for 18 weeks
Study: 9039155
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplementation (1500 mg of calcium per day)
Study: 8341042
Drug: .85 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: .85 g/kg alcohol
Study: 3669071
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice (parents allowed to choose between two antibiotics)
Study: 3669071
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice (parents not allowed to choose)
Study: 26035186
Drug: Vortioxetine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (both doses)
Study: 11438132
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg for 14 days
Study: 2551355
Drug: 2-drug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-4 and vincristine 1 mg i.v. days 1 + 4; every 4 weeks)
Study: 2551355
Drug: 4-drug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug chemotherapy regimen (cyclophosphamide 10 mg/kg i.v. days 1-3, vincristine 2 mg i.v. day 1 and 1 mg i.v. day 5, methotrexate 30 mg i.v. days 3 and 5, CCNU 80 mg/m2 i.v. day 2; every 7 weeks)
Study: 332438
Drug: Trimazosin, 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin, 900 mg daily
Study: 332438
Drug: Methyldopa, 2,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa, 2,250 mg daily
Study: 31587885
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg intravenously)
Study: 23275404
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly doses of milieu communication teaching (MCT)
Study: 23275404
Drug: 1 weekly
Normalized name: granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 weekly dose of milieu communication teaching (MCT)
Study: 19517231
Drug: Havrix (HAV)
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix (HAV) vaccine
Study: 19517231
Drug: TWINRIX (HAV/HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: TWINRIX (HAV/HBV combination vaccine)
Study: 19517231
Drug: Engerix (HBV)
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix (HBV) vaccine
Study: 17197592
Drug: Intracervical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical saline injection
Study: 9635947
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 75 mg/day
Study: 8162627
Drug: Colestipol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 10 g and Simvastatin 10 mg/day (CS)
Study: 8162627
Drug: Colestipol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 10 g and Bezafibrate 400 mg/day (CB)
Study: 2735338
Drug: Sucralfate tablets
Normalized name: Sucralfate Tablets
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate tablets
Study: 4985836
Drug: 5 ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Study: 4985836
Drug: 0.5 ml.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml. of packed group O R(2)R(2) cells, administered by intravenous injection
Study: 4985836
Drug: Initial antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial antibodies comprised 7S gammaG immunoglobulins with a minor 19S gammaM component in about half the cases
Study: 22420399
Drug: DynaClose topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynaClose topical tissue expansion device
Study: 18753738
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg orally t.i.d.)
Study: 17994436
Drug: Azithromycin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, single 1 gram dose
Study: 17994436
Drug: Topical tetracycline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline, twice per day for six weeks
Study: 15487810
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg once daily
Study: 15487810
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg every 12 hours
Study: 15487810
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg once daily plus gemfibrozil 600 mg every 12 hours
Study: 11571454
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 3x1 g/day for 14 days
Study: 11571454
Drug: No preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preemptive treatment (Control group)
Study: 11571454
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir 2x5 mg/kg body weight for 14 days (for those who developed CMV disease)
Study: 9804594
Drug: Cocaine administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administration (0.4 mg/kg)
Study: 7822675
Drug: Daily Disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Disposable Wear (DDW)
Study: 7822675
Drug: Conventional Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Daily Wear (CDW)
Study: 26865198
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence (cumulative medication adherence, ≥80%)
Study: 26865198
Drug: Poor adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor adherence (cumulative medication adherence, <50%)
Study: 26865198
Drug: Intermediate adherence
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate adherence (cumulative medication adherence, 50%-80%)
Study: 17218552
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium
Study: 9554820
Drug: s.c. rHu‐EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rHu‐EPO (2000 U/twice weekly)
Study: 9554820
Drug: s.c. rHu‐EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rHu‐EPO (3000 U twice weekly after 6 weeks if Hb increase was below 1 g%)
Study: 9554820
Drug: s.c. rHu‐EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rHu‐EPO therapy
Study: 8060471
Drug: Cyclosporin and
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin and prednisolone (double therapy)
Study: 8060471
Drug: Cyclosporin, prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin, prednisolone, and azathioprine (triple therapy)
Study: 28633774
Drug: Electric shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric shockwave therapy
Study: 21438131
Drug: Piperacillin/tazobactam (PIP/TAZO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIP/TAZO) 125 mg/kg every 8 hr
Study: 21438131
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 25 mg/kg every 6 hr
Study: 19569068
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI (high-dose tirofiban)
Study: 11071026
Drug: Latanoprost, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost, 50 microg/ml once daily
Study: 11071026
Drug: Timolol 5
Normalized name: timolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 5 mg/ml plus dorzolamide, 20 mg/ml twice daily
Study: 9071196
Drug: Early reperfusion
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early reperfusion therapy (within six hours)
Study: 9071196
Drug: Late reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late reperfusion therapy (after six hours)
Study: 2425315
Drug: Epidural hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural hydromorphone (1.0 mg in 10 mL preservative-free saline)
Study: 2425315
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (10 mL of 0.25%)
Study: 31525795
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of medications (CO)
Study: 27511740
Drug: Individual standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual standardized reminiscence therapy performed by trained nursing home volunteers
Study: 18835314
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (15 mg retinol equivalent) alongside the pentavalent vaccine
Study: 18835314
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation with pentavalent vaccine
Study: 16681880
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg/d
Study: 16681880
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg/d (HNPCC)
Study: 9369038
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment alone
Study: 3514233
Drug: Cisapride (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (slow i.v. injection)
Study: 3514233
Drug: Placebo (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (slow i.v. injection)